Company intelligence / Profile preview

Neovia Oncology

Seattle, Washington, United Statesneoviaoncology.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

A clinical-stage biotech developing multi-inhibitor drugs to overcome cancer resistance mechanisms. Their lead candidate NEV-801 showed curative potential in preclinical models of imatinib-resistant leukemia and multi-drug resistant colon cancer, with Phase I trials demonstrating early clinical evaluation of safety and pharmacokinetics[3][6][8].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

NEV-801

Beyond the preview

Go deeper on Neovia Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neovia Oncology.

Explore the full profile